Overview

The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors

Status:
Completed

Trial end date:
2020-09-09

Target enrollment:

Participant gender:

Summary

The Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Participants With Advanced Solid Tumors

Phase:

Phase 1

Details

Lead Sponsor:

BeiGene

Collaborator:

Myriad Genetic Laboratories, Inc.